Prostate-specific antigen (PSA) testing behavior did not significantly change in the years after a USPSTF recommendation against PSA screening.
Ibrutinib therapy carries a significantly higher risk of atrial fibrillation/flutter and all-grade bleeding compared with other treatments.
Magnetic resonance imaging (MRI) may be an effective tool for diagnosing hepatocellular carcinoma (HCC).
For patients with chronic myeloid leukemia, prolonged imatinib use helps achieve deeper molecular response with long-term treatment.
Nonwhite organ transplant recipients are at risk for developing non-melanoma skin cancer following transplantation.
TP53 and MDM2 alterations are associated with resistance to cisplatin and inferior progression-free survival among patients with metastatic germ cell tumors.
Alpha-fetoprotein (aFP) levels of at least 400 ng/mL predict patients with hepatocellular carcinoma (HCC) likely to respond to second-line ramucirumab.
Treatment with post-mastectomy radiotherapy (PMRT) reduces the risk for locoregional failure (LRF) recurrence and mortality.
The presence of circulating plasma cells (CPCs) predicts a worse prognosis for patients with multiple myeloma.
Response with low-dose ponatinib is similar to that of standard-dose ponatinib among patients with refractory chronic myeloid leukemia (CML).
Patients with chronic myeloid leukemia (CML) in accelerated phase may obtain less clinical benefit with first-line imatinib therapy.
Treatment with ibrutinib may be associated with favorable progression-free and overall survival as well as high overall response rate.
The FDA accepted a New Drug Application for neratinib for the extended treatment of patients with early HER2-positive breast cancer.
Treatment with single-agent dalantercept had favorable safety profile in recurrent or metastatic head and neck squamous cell carcinoma.
Bevacizumab should not be used with capecitabine as an adjuvant treatment for colorectal cancer.
The addition of rituximab to chemotherapy may benefit patients being treated for acute lymphoblastic leukemia (ALL).
In a large cohort of US veterans with multiple myeloma, statin therapy was associated with a decreased risk of all-cause and cancer-specific mortality.
Pneumonitis associated with PD-1/PD-L1 monoclonal antibodies is more common when given in combination with anti-CTLA-4 monoclonal antibodies.
Enrollment disparities in clinical trials improved between 1990 and 2012 for female and elderly patients with lung cancer.
Primary G-CSF was associated with low-to-modest benefit in lowering risk for neutropenia-related hospitalization.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Statins Linked to Improved Overall Survival in Multiple Myeloma
- Ghost and Honorary Authorship in Cancer Research
- Immune Checkpoint Inhibitors Continue to Transform Management of Advanced NSCLC
- Oral REP Regimen Active in Myeloma Refractory to Lenalidomide
- Minimal Residual Disease and Treatment Response in Multiple Myeloma
- PSA Testing Unchanged in Years After USPSTF Recommendation
- Risk of Arrhythmias, Bleeding Higher With Ibrutinib Therapy
- MRI May Be Effective Screening Test for Hepatocellular Carcinoma
- Prolonged Imatinib Therapy Linked With Deeper Molecular Response in CML-CP
- Emerging Prognostic Markers Continue to Improve Myeloma Treatment